Pfizer Faces $2 Billion Generic Drag On Revenues In 2008
Executive Summary
Loss of exclusivity for blockbuster drugs will weigh on Pfizer's top line in the coming year, just as the launch of generic versions of key drugs dragged on the pharma giant's revenues in 2007. Pfizer will face the loss of approximately $2 billion in sales from the loss of Zyrtec and Camptosar in 2008
You may also be interested in...
Pfizer Restructures for a More Flexible Future
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care, and emerging markets. These units join Pfizer's oncology and mature products businesses.
Pfizer Confident In Lipitor Backup Plan, But Wall Street Seems On The Fence
Although Pfizer maintains it has a reasonably failsafe plan in place to weather the loss of exclusivity for its blockbuster cholesterol drug Lipitor and other products in coming, Wall Street appears less confident in the drug maker's ability to come out ahead
Pfizer Confident In Lipitor Backup Plan, But Wall Street Seems On The Fence
Although Pfizer maintains it has a reasonably failsafe plan in place to weather the loss of exclusivity for its blockbuster cholesterol drug Lipitor and other products in coming, Wall Street appears less confident in the drug maker's ability to come out ahead